Newsletters
February 13, 2024
February 2024 Newsletter
More News
& publications
Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate
Targeting caspase-4/5 has the potential to address a broad range of inflammatory…
2026-2027 Budget: For a competitive and innovative Quebec in life sciences and health technologies
BIOQuébec submitted its pre-budget briefing paper, “For a competitive and innovative Québec in…
Acuitas Therapeutics Expands Collaboration with RNA Technologies & Therapeutics Through Strategic Investment
The investment will expand RNA Technologies & Therapeutics’ operations and …
